Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Current Cardiology Reports
Erschienen in: Current Cardiology Reports 11/2016

01.11.2016 | Valvular Heart Disease (A Wang, Section Editor)

Access Options for Transcatheter Aortic Valve Replacement in Patients with Unfavorable Aortoiliofemoral Anatomy

verfasst von: Jayendrakumar S. Patel, Amar Krishnaswamy, Lars G. Svensson, E. Murat Tuzcu, Stephanie Mick, Samir R. Kapadia

Erschienen in: Current Cardiology Reports | Ausgabe 11/2016

Einloggen, um Zugang zu erhalten

Abstract

In the current era, 10–15 % of transcatheter aortic valve replacement (TAVR)-eligible high and prohibitive risk patients with severe symptomatic aortic stenosis are not candidates for transfemoral arterial access. Knowledge of the various alternative access options can enable TAVR teams to provide improved quality of life and potentially life-saving treatment for a group of patients who otherwise have no viable options. In this article, we review approach to patients with unfavorable femoral arterial anatomy and provide an in-depth discussion on the various alternative routes for TAVR.
Literatur
1.
Dewey TM, Walther T, Doss M, et al. Transapical aortic valve implantation: an animal feasibility study. Ann Thorac Surg. 2006;82:110–6.CrossRefPubMed
2.•
Blackstone EH, Suri RM, Rajeswaran J, et al. Propensity-matched comparisons of clinical outcomes after transapical or transfemoral transcatheter aortic valve replacement: a placement of aortic transcatheter valves (PARTNER)-I trial substudy. Circulation. 2015;131:1989–2000. Compared TA with TF approach and found a higher liklihood of adverse periprocedural events and prolonged recovery with TA approach. Stroke risk was equivalent with both approaches.CrossRefPubMed
3.
Makkar RR, Fontana GP, Jilaihawi H, et al. Transcatheter aortic-valve replacement for inoperable severe aortic stenosis. N Engl J Med. 2012;366:1696–704.CrossRefPubMed
4.
Kapadia SR, Leon MB, Makkar RR, et al. 5-year outcomes of transcatheter aortic valve replacement compared with standard treatment for patients with inoperable aortic stenosis (PARTNER 1): a randomised controlled trial. Lancet. 2015;385:2485–91.CrossRefPubMed
5.
Leon MB, Smith CR, Mack M, et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med. 2010;363:1597–607.CrossRefPubMed
6.
Kapadia SR, Tuzcu EM, Makkar RR, et al. Long-term outcomes of inoperable patients with aortic stenosis randomly assigned to transcatheter aortic valve replacement or standard therapy. Circulation. 2014;130:1483–92.CrossRefPubMed
7.
Leon MB, Smith CR, Mack MJ, et al. Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients. N Engl J Med. 2016;374:1609–20.CrossRefPubMed
8.
Webb JG, Doshi D, Mack MJ, et al. A Randomized Evaluation of the SAPIEN XT Transcatheter Heart Valve System in Patients With Aortic Stenosis Who Are Not Candidates for Surgery. JACC Cardiovasc Interv. 2015;8:1797–806.CrossRefPubMed
9.
Kodali SK, O’Neill WW, Moses JW, et al. Early and late (one year) outcomes following transcatheter aortic valve implantation in patients with severe aortic stenosis (from the United States REVIVAL trial). Am J Cardiol. 2011;107:1058–64.CrossRefPubMed
10.
Aguirre J, Waskowski R, Poddar K, et al. Transcatheter aortic valve replacement: experience with the transapical approach, alternate access sites, and concomitant cardiac repairs. J Thorac Cardiovasc Surg. 2014;148:1417–22.CrossRefPubMed
11.
Al Kindi AH, Salhab KF, Roselli EE, Kapadia S, Tuzcu EM, Svensson LG. Alternative access options for transcatheter aortic valve replacement in patients with no conventional access and chest pathology. J Thorac Cardiovasc Surg. 2014;147:644–51.CrossRefPubMed
12.
Svensson LG, Dewey T, Kapadia S, et al. United States feasibility study of transcatheter insertion of a stented aortic valve by the left ventricular apex. Ann Thorac Surg. 2008;86:46–54. discussion 54-5.CrossRefPubMed
13.••
Svensson LG, Blackstone EH, Rajeswaran J, et al. Comprehensive analysis of mortality among patients undergoing TAVR: results of the PARTNER trial. J Am Coll Cardiol. 2014;64:158–68. Demonstrated an elevated periprocedural risk associated with TA approach over TF approach.CrossRefPubMed
14.
Thourani VH, Kodali S, Makkar RR, et al. Transcatheter aortic valve replacement versus surgical valve replacement in intermediate-risk patients: a propensity score analysis. Lancet. 2016.
15.
Kodali S, Thourani VH, White J, et al. Early clinical and echocardiographic outcomes after SAPIEN 3 transcatheter aortic valve replacement in inoperable, high-risk and intermediate-risk patients with aortic stenosis. Eur Heart J. 2016.
16.
Ducrocq G, Francis F, Serfaty JM, et al. Vascular complications of transfemoral aortic valve implantation with the Edwards SAPIEN prosthesis: incidence and impact on outcome. EuroIntervention. 2010;5:666–72.CrossRefPubMed
17.•
Krishnaswamy A, Parashar A, Agarwal S, et al. Predicting vascular complications during transfemoral transcatheter aortic valve replacement using computed tomography: a novel area-based index. Catheter Cardiovasc Interv. 2014;84:844–51. Found that a sheath to femoral artery diameter and area ratios predict vascular complications in patients undergoing TF TAVR.CrossRefPubMed
18.
Ziegelmueller JA, Lange R, Bleiziffer S. Access and closure of the left ventricular apex: state of play. J Thorac Dis. 2015;7:1548–55.PubMedPubMedCentral
19.
Kodali SK, Williams MR, Smith CR, et al. Two-year outcomes after transcatheter or surgical aortic-valve replacement. N Engl J Med. 2012;366:1686–95.CrossRefPubMed
20.
Mack MJ, Leon MB, Smith CR, et al. 5-year outcomes of transcatheter aortic valve replacement or surgical aortic valve replacement for high surgical risk patients with aortic stenosis (PARTNER 1): a randomised controlled trial. Lancet. 2015;385:2477–84.CrossRefPubMed
21.
Thourani VH, Jensen HA, Babaliaros V, et al. Outcomes in Nonagenarians Undergoing Transcatheter Aortic Valve Replacement in the PARTNER-I Trial. Ann Thorac Surg. 2015;100:785–92. discussion 793.CrossRefPubMed
22.
Williams M, Kodali SK, Hahn RT, et al. Sex-related differences in outcomes after transcatheter or surgical aortic valve replacement in patients with severe aortic stenosis: insights from the PARTNER Trial (Placement of Aortic Transcatheter Valve). J Am Coll Cardiol. 2014;63:1522–8.CrossRefPubMed
23.•
Thourani VH, Jensen HA, Babaliaros V, et al. Transapical and Transaortic Transcatheter Aortic Valve Replacement in the United States. Ann Thorac Surg. 2015;100:1718–26. discussion 1726-7. Found no difference in mortality or stroke between TA and DA access.
24.
Thomas M, Schymik G, Walther T, et al. Thirty-day results of the SAPIEN aortic Bioprosthesis European Outcome (SOURCE) Registry: a European registry of transcatheter aortic valve implantation using the Edwards SAPIEN valve. Circulation. 2010;122:62–9.CrossRefPubMed
25.
Webb JG, Altwegg L, Boone RH, et al. Transcatheter aortic valve implantation: impact on clinical and valve-related outcomes. Circulation. 2009;119:3009–16.CrossRefPubMed
26.
Himbert D, Descoutures F, Al-Attar N, et al. Results of transfemoral or transapical aortic valve implantation following a uniform assessment in high-risk patients with aortic stenosis. J Am Coll Cardiol. 2009;54:303–11.CrossRefPubMed
27.
Smith CR, Leon MB, Mack MJ, et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med. 2011;364:2187–98.CrossRefPubMed
28.
Ewe SH, Delgado V, Ng AC, et al. Outcomes after transcatheter aortic valve implantation: transfemoral versus transapical approach. Ann Thorac Surg. 2011;92:1244–51.CrossRefPubMed
29.
Genereux P, Cohen DJ, Williams MR, et al. Bleeding complications after surgical aortic valve replacement compared with transcatheter aortic valve replacement: insights from the PARTNER I Trial (Placement of Aortic Transcatheter Valve). J Am Coll Cardiol. 2014;63:1100–9.CrossRefPubMed
30.
Kodali S, Williams MR, Doshi D, et al. Sex-specific differences at presentation and outcomes among patients undergoing transcatheter aortic valve replacement: a cohort study. Ann Intern Med. 2016;164:377–84.CrossRefPubMed
31.
Lefevre T, Kappetein AP, Wolner E, et al. One year follow-up of the multi-centre European PARTNER transcatheter heart valve study. Eur Heart J. 2011;32:148–57.CrossRefPubMed
32.
Gada H, Kirtane AJ, Wang K, et al. Temporal trends in quality of life outcomes after transapical transcatheter aortic valve replacement: a placement of AoRTic TraNscathetER Valve (PARTNER) Trial Substudy. Circ Cardiovasc Qual Outcomes. 2015;8:338–46.CrossRefPubMedPubMedCentral
33.•
Rahnavardi M, Santibanez J, Sian K, Yan TD. A systematic review of transapical aortic valve implantation. Ann Cardiothorac Surg. 2012;1:116–28. Systematic review of the TA approach demonstrating safety and efficacy.PubMedPubMedCentral
34.
Walther T, Simon P, Dewey T, et al. Transapical minimally invasive aortic valve implantation: multicenter experience. Circulation. 2007;116:I240–5.CrossRefPubMed
35.
Rodes-Cabau J, Webb JG, Cheung A, et al. Transcatheter aortic valve implantation for the treatment of severe symptomatic aortic stenosis in patients at very high or prohibitive surgical risk: acute and late outcomes of the multicenter Canadian experience. J Am Coll Cardiol. 2010;55:1080–90.CrossRefPubMed
36.
Walther T, Thielmann M, Kempfert J, et al. PREVAIL TRANSAPICAL: multicentre trial of transcatheter aortic valve implantation using the newly designed bioprosthesis (SAPIEN-XT) and delivery system (ASCENDRA-II). Eur J Cardiothorac Surg. 2012;42:278–83. discussion 283.CrossRefPubMed
37.•
Walther T, Thielmann M, Kempfert J, et al. One-year multicentre outcomes of transapical aortic valve implantation using the SAPIEN XT valve: the PREVAIL transapical study. Eur J Cardiothorac Surg. 2013;43:986–92. Studied newer generation Sapien XT device delivery system.CrossRefPubMed
38.•
Biancari F, Rosato S, D’Errigo P, et al. Immediate and Intermediate Outcome After Transapical Versus Transfemoral Transcatheter Aortic Valve Replacement. Am J Cardiol. 2016;117:245–51. Demonstrated higher survival with TF approach over TA approach.CrossRefPubMed
39.•
Suri RM, Minha S, Alli O et al. Learning curves for transapical transcatheter aortic valve replacement in the PARTNER-I trial: technical performance, success, and safety. J Thorac Cardiovasc Surg. 2016. Highlights the existence of a learning curve for TA-TAVR.
40.
Unbehaun A, Pasic M, Drews T, et al. Analysis of survival in 300 high-risk patients up to 2.5 years after transapical aortic valve implantation. Ann Thorac Surg. 2011;92:1315–23.CrossRefPubMed
41.
Ye J, Cheung A, Lichtenstein SV, et al. Transapical transcatheter aortic valve implantation: follow-up to 3 years. J Thorac Cardiovasc Surg. 2010;139:1107-13. 1113 e1.
42.
Kempfert J, Rastan A, Holzhey D, et al. Transapical aortic valve implantation: analysis of risk factors and learning experience in 299 patients. Circulation. 2011;124:S124–9.CrossRefPubMed
43.•
Dewey TM, Bowers B, Thourani VH, et al. Transapical aortic valve replacement for severe aortic stenosis: results from the nonrandomized continued access cohort of the PARTNER trial. Ann Thorac Surg. 2013;96:2083–9. Highlights the existence of a learning curve for TA-TAVR.CrossRefPubMed
44.
Eggebrecht H, Schmermund A, Voigtlander T, Kahlert P, Erbel R, Mehta RH. Risk of stroke after transcatheter aortic valve implantation (TAVI): a meta-analysis of 10,037 published patients. EuroIntervention. 2012;8:129–38.CrossRefPubMed
45.••
Thourani VH, Li C, Devireddy C, et al. High-risk patients with inoperative aortic stenosis: use of transapical, transaortic, and transcarotid techniques. Ann Thorac Surg. 2015;99:817–23. discussion 823-5. Demonstrated excellent outcomes with alternative access TAVR in patients with unfavorable TF access.
46.
Thourani VH, Gunter RL, Neravetla S, et al. Use of transaortic, transapical, and transcarotid transcatheter aortic valve replacement in inoperable patients. Ann Thorac Surg. 2013;96:1349–57.CrossRefPubMed
47.
Moat NE, Ludman P, de Belder MA, et al. Long-term outcomes after transcatheter aortic valve implantation in high-risk patients with severe aortic stenosis: the U.K. TAVI (United Kingdom Transcatheter Aortic Valve Implantation) Registry. J Am Coll Cardiol. 2011;58:2130–8.CrossRefPubMed
48.
Erdoes G, Basciani R, Huber C, et al. Transcranial Doppler-detected cerebral embolic load during transcatheter aortic valve implantation. Eur J Cardiothorac Surg. 2012;41:778–83. discussion 783-4.CrossRefPubMed
49.
Rodes-Cabau J, Dumont E, Boone RH, et al. Cerebral embolism following transcatheter aortic valve implantation: comparison of transfemoral and transapical approaches. J Am Coll Cardiol. 2011;57:18–28.CrossRefPubMed
50.
Schafer U, Ho Y, Frerker C, et al. Direct percutaneous access technique for transaxillary transcatheter aortic valve implantation: “the Hamburg Sankt Georg approach”. JACC Cardiovasc Interv. 2012;5:477–86.CrossRefPubMed
51.
Fraccaro C, Napodano M, Tarantini G, et al. Expanding the eligibility for transcatheter aortic valve implantation the trans-subclavian retrograde approach using: the III generation CoreValve revalving system. JACC Cardiovasc Interv. 2009;2:828–33.CrossRefPubMed
52.
Adamo M, Fiorina C, Curello S, et al. Role of different vascular approaches on transcatheter aortic valve implantation outcome: a single-center study. J Cardiovasc Med (Hagerstown). 2015;16:279–85.CrossRef
53.
Petronio AS, De Carlo M, Bedogni F, et al. Safety and efficacy of the subclavian approach for transcatheter aortic valve implantation with the CoreValve revalving system. Circ Cardiovasc Interv. 2010;3:359–66.CrossRefPubMed
54.•
Petronio AS, De Carlo M, Bedogni F, et al. 2-year results of CoreValve implantation through the subclavian access: a propensity-matched comparison with the femoral access. J Am Coll Cardiol. 2012;60:502–7. Provides evidence for subclavian TAVR.CrossRefPubMed
55.•
Ciuca C, Tarantini G, Latib A, et al. Trans-subclavian versus transapical access for transcatheter aortic valve implantation: a multicenter study. Catheter Cardiovasc Interv. 2016;87:332–8. Demonstrated equivalent 1 and 2 year survival rates between subclavian and TA access.CrossRefPubMed
56.
Bapat VN, Attia RQ, Thomas M. Distribution of calcium in the ascending aorta in patients undergoing transcatheter aortic valve implantation and its relevance to the transaortic approach. JACC Cardiovasc Interv. 2012;5:470–6.CrossRefPubMed
57.
Okuyama K, Jilaihawi H, Mirocha J, et al. Alternative access for balloon-expandable transcatheter aortic valve replacement: comparison of the transaortic approach using right anterior thoracotomy to partial J-sternotomy. J Thorac Cardiovasc Surg. 2015;149:789–97.CrossRefPubMed
58.
Seiffert M, Schnabel R, Conradi L, et al. Predictors and outcomes after transcatheter aortic valve implantation using different approaches according to the valve academic research consortium definitions. Catheter Cardiovasc Interv. 2013;82:640–52.PubMed
59.•
Ramlawi B, Abu Saleh WK, Jabbari OA, et al. Short-Term Outcomes with Direct Aortic Access for Transcatheter Aortic Valve Replacement. J Heart Valve Dis. 2015;24:426–32. Provides short term data for the direct aortic approach.PubMed
60.
Lardizabal JA, O’Neill BP, Desai HV, et al. The transaortic approach for transcatheter aortic valve replacement: initial clinical experience in the United States. J Am Coll Cardiol. 2013;61:2341–5.CrossRefPubMed
61.
Suri RM, Gulack BC, Brennan JM, et al. Outcomes of Patients With Severe Chronic Lung Disease Who Are Undergoing Transcatheter Aortic Valve Replacement. Ann Thorac Surg. 2015;100:2136–45. discussion 2145-6.CrossRefPubMed
62.
Azmoun A, Amabile N, Ramadan R, et al. Transcatheter aortic valve implantation through carotid artery access under local anaesthesia. Eur J Cardiothorac Surg. 2014;46:693–8. discussion 698.CrossRefPubMed
63.
Modine T, Sudre A, Delhaye C, et al. Transcutaneous aortic valve implantation using the left carotid access: feasibility and early clinical outcomes. Ann Thorac Surg. 2012;93:1489–94.CrossRefPubMed
64.•
Mylotte D, Sudre A, Teiger E, et al. Transcarotid transcatheter aortic valve replacement: feasibility and safety. JACC Cardiovasc Interv. 2016;9:472–80. Describes safety and efficacy of transcarotid approach.CrossRefPubMed
65.•
Lederman RJ, Babaliaros VC, Greenbaum AB. How to perform transcaval access and closure for transcatheter aortic valve implantation. Catheter Cardiovasc Interv. 2015;86:1242–54. Excellent description of technique for transcaval TAVR.CrossRefPubMedPubMedCentral
66.
Greenbaum AB, O’Neill WW, Paone G, et al. Caval-aortic access to allow transcatheter aortic valve replacement in otherwise ineligible patients: initial human experience. J Am Coll Cardiol. 2014;63:2795–804.CrossRefPubMedPubMedCentral
67.
Greenbaum A. Transcaval TAVR: technique, rationale, and complications. Transcatheter Valve Therapeutics annual meeting. Chicago, Illinois, June 4, 2015.
68.
Martinez-Clark PO, Singh V, Cadena JA, et al. Transcaval retrograde transcatheter aortic valve replacement for patients with no other access: first-in-man experience with CoreValve. JACC Cardiovasc Interv. 2014;7:1075–7.CrossRefPubMed
69.
Cribier A, Eltchaninoff H, Tron C, et al. Early experience with percutaneous transcatheter implantation of heart valve prosthesis for the treatment of end-stage inoperable patients with calcific aortic stenosis. J Am Coll Cardiol. 2004;43:698–703.CrossRefPubMed
70.
Cribier A, Eltchaninoff H, Tron C, et al. Treatment of calcific aortic stenosis with the percutaneous heart valve: mid-term follow-up from the initial feasibility studies: the French experience. J Am Coll Cardiol. 2006;47:1214–23.CrossRefPubMed
71.•
Cohen MG, Singh V, Martinez CA, et al. Transseptal antegrade transcatheter aortic valve replacement for patients with no other access approach - a contemporary experience. Catheter Cardiovasc Interv. 2013;82:987–93. Contemporary experience with the transseptal approach.CrossRefPubMed
Metadaten
Titel
Access Options for Transcatheter Aortic Valve Replacement in Patients with Unfavorable Aortoiliofemoral Anatomy
verfasst von
Jayendrakumar S. Patel
Amar Krishnaswamy
Lars G. Svensson
E. Murat Tuzcu
Stephanie Mick
Samir R. Kapadia
Publikationsdatum
01.11.2016
Verlag
Springer US
Erschienen in
Current Cardiology Reports / Ausgabe 11/2016
Print ISSN: 1523-3782
Elektronische ISSN: 1534-3170
DOI
https://doi.org/10.1007/s11886-016-0788-8

Weitere Artikel der Ausgabe 11/2016

Current Cardiology Reports 11/2016 Zur Ausgabe

Hypertension (AJ Peixoto and DS Geller, Section Editors)

Integrating Out-of-Office Blood Pressure in the Diagnosis and Management of Hypertension

Heart Failure (MR Mehra and E Joyce, Section Editors)

Gender Disparities Across the Spectrum of Advanced Cardiac Therapies: Real or Imagined?

Public Health Policy (T Gaziano, Section Editor)

Cardiovascular Complications of HIV in Endemic Countries

Lipid Abnormalities and Cardiovascular Prevention (G De Backer, Section Editor)

Progressing Insights into the Role of Dietary Fats in the Prevention of Cardiovascular Disease

Diabetes and Cardiovascular Disease (S Malik, Section Editor)

Integrating Biomarkers and Imaging for Cardiovascular Disease Risk Assessment in Diabetes

Echocardiography (JM Gardin, Section Editor)

Normal Variants in Echocardiography

Neu im Fachgebiet Kardiologie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

21.05.2024 TAVI Nachrichten

Bei schwerer Aortenstenose und obstruktiver KHK empfehlen die Leitlinien derzeit eine chirurgische Kombi-Behandlung aus Klappenersatz plus Bypass-OP. Diese Empfehlung wird allerdings jetzt durch eine aktuelle Studie infrage gestellt – mit überraschender Deutlichkeit.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen